Company: REVB
Filing Date: 2025-05-20
Form Type: S-1
Source: 0001213900-25-045828
Chunk: 211

Company: REVELATION BIOSCIENCES, INC.
Filing Date: 2025-05-20
Form: S-1
Chunk 211
---
of a private placement on January 25, 2022 (“PIPE Investment”), the Company issued warrants to an institutional investor
to purchase up to shares of common stock at an exercise price of $ per share (the “Class A Common Stock
Warrants”), valued on the PIPE Investment purchase date in the aggregate at $ million and included in the issuance costs
of the PIPE Investment and treated as equity. The warrants were exercisable immediately upon issuance, provide for a cash or cashless
exercise right and expire on .

The fair value of the Class A
Common Stock Warrants were estimated using the Black-Scholes option pricing model with the following assumptions:

| Volatility              |     |   47 | % |
| Expected term (years)   |     |    5 |   |
| Risk-free interest rate |     | 1.54 | % |
| Expected dividend yield |     |  0.0 | % |

Class A Placement Agent Common Stock Warrants

In connection with the PIPE
Investment, the Company issued warrants to Roth to purchase an aggregate of shares of common stock at an exercise price of $ per
share (the “Class A Placement Agent Common Stock Warrants”), valued on the PIPE Investment purchase date in the aggregate
at $ million and included in the issuance costs of the PIPE Investment and treated as equity. The warrants were exercisable immediately
upon issuance, provide for a cash or cashless exercise right and expire on .

The fair value of the Class A
Placement Agent Common Stock Warrants were estimated using the Black-Scholes option pricing model with the following assumptions:

| Volatility              |     |   47 | % |
| Expected term (years)   |     |    5 |   |
| Risk-free interest rate |     | 1.54 | % |
| Expected dividend yield |     |  0.0 | % |

Class B Common Stock Warrants

In connection with closing
of a public offering on July 28, 2022 (“the July 2022 Public Offering”), the Company issued and has outstanding
warrants to purchase an aggregate of shares of common stock at an exercise price of $ per share (the
“Class B Common Stock Warrants”), valued on the public offering purchase date in the aggregate at $ million and
included in the issuance costs of the public offering and treated as equity. The warrants were exercisable immediately upon issuance,
provide for a cash or cashless exercise right and expire on .

The fair value of the